AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance

U.S. Markets closed

AstraZeneca PLC (AZN.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,468.50-112.00 (-2.45%)
At close: 5:11PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close4,580.50
Open4,545.00
Bid4,460.00 x 6100
Ask4,556.00 x 13000
Day's Range4,464.50 - 4,615.57
52 Week Range3,680.00 - 5,505.00
Volume4,155,412
Avg. Volume2,845,576
Market Cap56.54B
Beta0.46
PE Ratio (TTM)22.93
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (4.97%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Financial Times9 hours ago

    [$$] GSK appoints AstraZeneca executive as global head of pharma

    GlaxoSmithKline has poached its new global head of pharmaceuticals from rival AstraZeneca, marking a change of guard at Britain's biggest drugmaker as it prepares for the arrival of its new chief executive. ...

  • Reuters17 hours ago

    GSK grabs Astra executive to replace pharma head

    LONDON/DAVOS, Switzerland, Jan 19 (Reuters) - G laxoSmithKline's global head of pharmaceuticals, Abbas Hussain, is to leave Britain's biggest drugmaker after being passed over for the top job and will be replaced by Luke Miels from AstraZeneca. Hussain, the brother of former England cricket captain Nasser Hussain, had been a contender to take over from Chief Executive Andrew Witty, who steps down at the end of March, but the job went to GSK's consumer health boss Emma Walmsley.

  • AstraZeneca Offers Update on Immuno-Oncology Program
    Zacks2 days ago

    AstraZeneca Offers Update on Immuno-Oncology Program

    AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.